Top 10 Breakthrough Cancer Pain Medication Developers Discussed in Research Facts Report Available at MarketPublishers.com

04 Oct 2013 • by Natalie Aster

LONDON – The prevalence of breakthrough pain in patients with cancer is estimated at anywhere between 19% and 95%. Approximately two-thirds of more than 1,095 cancer patients studied on one international research experienced breakthrough pain. Breakthrough pain can spoil the patient’s quality of life; it can also result in a slew of psychological and physical problems as well as lead to certain social complications.

This transient exacerbation of cancer pain considerably increases the use of healthcare services. The cost of taking care of the patients suffering from breakthrough pain is estimated at around USD 12 thousand per annum. As a comparison, the cost of caring for the patients without this pain is estimated at nearly USD 2.4 thousand.

In-demand research report “The Top 10 Developers of Breakthrough Cancer Pain Medications” created by Research Facts offers vital information on global top 10 developers of breakthrough cancer pain medications.

The report presents comprehensive profiles of the top 10 developers of breakthrough cancer pain medications. Each company profile includes each company’s contact details along with insightful information on key decision makers. It also examines such specialized fields as turnover, foreign trade, company description, etc. Data on company location status, ownership, product portfolio are available as well.

Report Details:

The Top 10 Developers of Breakthrough Cancer Pain Medications
Published: April, 2013
Pages: 58
Price: US$ 931.00

Other In-Demand Market Research Studies by Research Facts Include:

More in-demand research reports by the publisher can be found at Research Facts page.

CONTACTS

The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com